We report a right atrial myxoma which suddenly developed in a thalassemic patient after allogeneic bone marrow transplantation. The tumor was first detected by echocardiography on day +47 after transplant and the patient underwent surgical removal of the myxoma on day +103. The post-operative course was uneventful, and at more than 3 years from the event, he is alive and well, cured from his congenital disease, with no detectable intra-cardiac tumor. The onset of the myxoma in the early post-transplant period and the extremely high velocity of growth suggest a possible relationship of this condition with the immunosuppressive status. Keywords: myxoma; BMT; thalassemia Bone marrow transplantation (BMT) is a situation which may allow the development of rare and sometimes unrecognised complications 1,2 due to the conditioning regimen, immunosuppression, graft-versus-host disease (GVHD) etc. Cardiac myxoma is a rare form of heart tumor whose origin is still under discussion.
Bone marrow transplantation (BMT) is a situation which may allow the development of rare and sometimes unrecognised complications 1, 2 due to the conditioning regimen, immunosuppression, graft-versus-host disease (GVHD) etc. Cardiac myxoma is a rare form of heart tumor whose origin is still under discussion. 3, 4 Here, we report the occurrence of a right atrial myxoma in a young thalassemic patient in the early period after BMT.
Case report
The patient was a 17-year-old male suffering from homozygous B thalassemia, referred to our Unit in August 1994 to be evaluated for allogeneic BMT. Following the Pesaro classification system 5 he was evaluated as a class 3 patient. A complete clinical and echocardiographic evaluation was performed before the transplant; twice in his home town and once in Pesaro. Diagnostic conclusions were consistent between the three different cardiologists and showed mild left ventricle dilatation (5.3 cm) with normal myocardial wall thickness and normal regional and global systolic function. No morphological abnormalities were observed in the right heart. The patient underwent BMT on 1 September 1994 from his HLA-identical brother. Preparation for BMT was performed following the scheme at that time in use for class 3 patients 6 (busulfan 14 mg/kg over 4 consecutive days followed by cyclophosphamide 120 mg/kg over 4 days and anti-lymphocytic globulin 2 ml/kg from day −8 to day −2). The early post-BMT course was uneventful and the patient was discharged on day +16 with documented allogeneic engraftment. Because of severe metabolic problems (fasting serum glucose: 44 mmol/l, serum triglycerides: 33 mmol/l) he was readmitted to the ward on day +34. During hospitalization he experienced two episodes of symptomatic hypotension (blood pressure 80/40 mm Hg). Echocardiographic examination performed on 18 October (day +47) revealed 'a large intra-cardiac tumor (oval in shape with maximum diameter = 3.1 cm) with ultrasound density similar to the myocardium, immotile, attached to the lateral wall of the right atrium, below the tricuspid anulus, near to the apex of the central venous catheter, without doppler findings of valve orifice stenosis' (Figure 1 ). After initial anticoagulant treatment, a MRI scan ( Figure 2 ) was performed (27 October, day +56) which confirmed the presence of tumor, excluded a thrombotic origin, but did not permit a definitive diagnosis. He was also investigated for various infections: Epstein-Barr virus (EBV), cytomegalovirus (CMV), bacterial and fungal infections. All tests were negative except for a CMV viremia. He underwent surgical resection of the right atrial mass via a right atriotomy 7-9 on day 103 post BMT. A solid intra-cardiac tumor (diameter 2.7 cm) was removed; histological examination and immunohistochemistry confirmed a diagnosis of myxoma with thrombosis (Table 1 describes materials and methods used for the histology and immunophenotyping. Figures 3 and 4  (a and b) show microphotographs of the tumor sections). The post-surgery course was complicated by an episode of pneumonia. The patient returned from the surgical ward on day +118 and was discharged on day +125. On day +149 he returned to his home town on anticoagulant therapy. He was subsequently examined 6, 12, 24 and 36 months after the transplant. Echocardiographic and MRI examinations were negative for intra-cardiac lesions. Other cardiac parameters were similar to those found pre-transplant. The patient is currently alive and well, cured from his congenital disease and off immunosuppressive therapy.
Discussion
Cardiac myxomas represent approximately 50% of primary tumors of the heart and can occur in two forms: sporadic and familiar. Sporadic tumors are more common in middleaged women while the familiar forms are associated with different conditions: cutaneous lentiginosis, cutaneous myxomas, adrenocortical nodular dysplasia, Cushing's syndrome, testicular tumors. Even if they are histologically benign these tumors may be lethal because of their strategic position; in addition, some cases of malignant atrial myxomas have been reported. [10] [11] [12] Myxomas usually develop in the atria, more frequently in the left atrium (75%), but they can arise both in the right atrium and in other parts of the heart. They seem to take origin from the endocardium, but because of particular immunohistochemical and histological features a neural origin has also been postulated. 3 Clinically, myxomas can present with different symptoms depending on their position, size and mobility. Systemic embolism, dyspnea, heart failure, hypotension, pulmonary edema and other non-specific non-cardiac signs (fever, malaise, arthralgia, etc) can be variously present. Echocardiography, computed tomography (CT) and MRI currently remain the most important non-invasive diagnostic imaging methods, while prompt surgical resection is the treatment of choice. Because myxomas are rare tumors and their pathogenesis is not clearly understood in relation to an immunosuppressed status as in this setting, we attempted to identify a possible relationship with the BMT procedure. Many complications can occur after transplant including toxicity, infections and secondary tumors. In this case the observation of a solid intra-cardiac mass required a differential diagnosis from other proliferative disorders or infectious complications. In addition, the location also suggested the possibility of a thrombotic event in a patient with a long-term central venous catheter. The post-surgical diagnosis of cardiac myxoma was an unusual finding, because this kind of tumor is not reported in transplant recipients or in general in immuno-compromised hosts. The immunosuppression may have been implicated in view of the extremely high velocity of growth of the tumor. Different authors 13, 14 have suggested that primary intra-cardiac myxomas grow rapidly, but the growth rate of these tumors has always been difficult to determine and has generally been determined for recurrent lesions. In a paper from Malekzadeh and Roberts 15 the interval from first surgical excision to surgery for recurrent myxoma ranged from 11 to 76 months (mean 33 months); in the same study the recurrent myxomas increased in size with an average of 0.15 cm/month. The case described here had the fastest growth reported in the literature (about 1.35 cm/month). The patient was profoundly immunosuppressed with cyclosporin A; he did not discontinue any treatment and had a good immunologic recovery post-transplant. Since late recurrences are possible, long-term clinical and echocardiographic follow-up will be undertaken.
